We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
ACCEPT
  • Patients & Caregivers

    Patients & Caregivers

    • Patient Advocacy
    • Patient Support
    • Find Community PPD Support Resources
  • Healthcare Providers

    Healthcare Providers

    • Visit the Sage Medical Hub
  • Our Medicines
  • Therapeutic Focus

    Therapeutic Focus

    • A New Approach to Brain Health Disorders
    • GABA & NMDA Receptors
  • Programs & Research

    Programs & Research

    • Depressive Disorders
    • Neurologic Disorders
    • Neuropsychiatric Disorders
    • Pipeline
    • Clinical Trials
    • Publications
    • Collaborations
  • About Us

    About Us

    • Mission & Values
    • Corporate Governance
    • Our Team
    • Partnering
    • Corporate Social Responsibility
  • Working at Sage
  • Investors/Media
  • Clinical Trials
  • Contact Us

Seeing the brain differently
makes a world of difference

LEARN MORE ABOUT OUR APPROACH

News The latest from Sage

Press Releases

Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

Events

Sage Therapeutics Q3 2020 Financial Results Conference Call

In the news

Learn more about the Sage Therapeutics Brand

See All News

Patients & Caregivers Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by CNS disorders.

Postpartum Depression

Major Depressive Disorder

Patient Advocacy Programs

See Our Resources for Patients

Healthcare Providers It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to discover new pathways to brain health by making medicines that matter so patients can get better, sooner.

Learn More About Our Approach

Clinical Trials A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering CNS disorders.

Learn More About Our Ongoing Clinical Trials

Pipeline Advancing a Leading Brain Health Portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential CNS therapeutics.

Learn More About Our Programs and Research

Careers Rethinking CNS to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

Experience Our Culture

Patients & Caregivers

  • Patient Advocacy
  • Patient Support
  • Find Community PPD Support Resources

Healthcare Providers

  • Visit the Sage Medical Hub

Our Medicines

Therapeutic Focus

  • A New Approach to Brain Health Disorders
  • GABA & NMDA Receptors

Programs & Research

  • Depressive Disorders
  • Neurologic Disorders
  • Neuropsychiatric Disorders
  • Pipeline
  • Clinical Trials
  • Publications
  • Collaborations

About Us

  • Mission & Values
  • Corporate Governance
  • Our Team
  • Partnering
  • Corporate Social Responsibility

Working at Sage

  • Investors/Media
  • Clinical Trials
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

© 2020 Sage Therapeutics, Inc

  • Privacy Policy
  • Terms of Use
  • Community Guidelines
  • Accessibility
  • Site Map

SAGE CENTRAL, the SAGE CENTRAL logo, ZULRESSO, the ZULRESSO logo, SAGE THERAPEUTICS, and the SAGE THERAPEUTICS logo are trademarks of Sage Therapeutics, Inc.
All other trademarks referenced herein are the property of their respective owners.

You are now leaving SageRX.com and entering one that is not owned or controlled by Sage Therapeutics, Inc.

Sage Therapeutics, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Sage Therapeutics, Inc. does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue